Physician profile
Anthony Aversa
NPI 1154309623
$9,341.35
in general payments reported to CMS, 2019-2025
30 companies · $1,237 in 2025
The $1,237 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,222 · 2020: $666 · 2021: $863 · 2022: $1,582 · 2023: $1,786 · 2024: $1,984 · 2025: $1,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,559 · Education: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,559.37 |
| Education | $448.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,486.41 | 2019-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $1,303.94 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $1,049.18 | 2019-2025 | Tremfya, Remicade, Stelara |
| Sun Pharmaceutical Industries INC. | $837.54 | 2020-2025 | Ilumya |
| Ucb, INC. | $769.93 | 2019-2024 | Bimzelx, Cimzia |
| Lilly USA, LLC | $577.41 | 2019-2025 | Olumiant, Ebglyss, Taltz |
| E.R. Squibb & Sons, L.L.C. | $518.20 | 2022-2025 | Sotyktu |
| Pfizer INC. | $478.02 | 2019-2025 | |
| Amgen INC. | $448.77 | 2019-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $408.32 | 2019-2025 | |
| Genzyme Corporation | $313.23 | 2019-2025 | |
| Galderma Laboratories, L.P. | $196.29 | 2019-2025 | Nemluvio |
| Organon LLC | $194.50 | 2024-2025 | Hadlima, Vtama |
| Regeneron Healthcare Solutions, INC. | $149.22 | 2019-2025 | Libtayo |
| Arcutis Biotherapeutics, INC. | $99.57 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2020 | |
| Incyte Corporation | $78.55 | 2022-2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.79 | 2022-2024 | Spevigo |
| Dermavant Sciences, INC. | $42.76 | 2023 | Vtama |
| Genentech USA, INC. | $40.40 | 2019 | |
| Biofrontera INC. | $37.58 | 2019-2022 | |
| Kyowa Kirin, INC. | $25.83 | 2023 | Poteligeo |
| Paratek Pharmaceuticals, INC. | $23.83 | 2025 | Nuzyra |
| Dermira, INC. | $21.68 | 2020 | |
| Sandoz INC. | $18.89 | 2023 | Hyrimoz |
| Solta Medical, A Division of Bausch Health US, LLC | $18.19 | 2025 | Clear & Brilliant |
| Merck Sharp & Dohme LLC | $17.84 | 2019 | |
| Blueprint Medicines Corporation | $16.14 | 2025 | Ayvakit |
| Verrica Pharmaceuticals INC. | $14.17 | 2024 | Ycanth |
| Dusa Pharmaceuticals, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Aversa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.